TG prelims beat views

 Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively

Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million

https://www.globenewswire.com/news-release/2025/01/14/3009177/8790/en/TG-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2024-Net-Revenue-and-2025-Anticipated-Development-Milestones.html